BeOne Medicines price target raised to $477 from $454 at TD Cowen
TD Cowen raised the firm’s price target on BeOne Medicines (ONC) to $477 from $454 and keeps a Buy rating on the shares. The firm updated its model following beat…
Fiscal Year: January - December
BeOne Medicines AG (ONC), listed on the NASDAQ, has a market capitalization of $46.49B. As of Nov 07, 2026, the stock is trading at $406.96 per share@else an unavailable price , offering investors a clear view of its current market value. BeOne Medicines AG is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 52.07, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. BeOne Medicines AG also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that BeOne Medicines AG (ONC) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for BeOne Medicines AG is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for BeOne Medicines AG, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for BeOne Medicines AG is 32.08, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, BeOne Medicines AG (ONC) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether BeOne Medicines AG (ONC) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of BeOne Medicines AG (ONC) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of BeOne Medicines AG. To access the full SS Score, consider upgrading your subscription.
BeOne Medicines AG is a significant player in the industry sector, with a market capitalization of $46.49B and a competitive P/E ratio of 52.07. Investors should compare these metrics with industry peers to gauge whether BeOne Medicines AG is outperforming or underperforming within its sector.
TD Cowen raised the firm’s price target on BeOne Medicines (ONC) to $477 from $454 and keeps a Buy rating on the shares. The firm updated its model following beat…
Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $465 from $425 and keeps an Overweight rating on the shares.
BeOne Medicines NASDAQ: ONC raised its 2026 revenue and operating income forecasts after third-quarter sales of its cancer drug BRUKINSA topped $1 billion in the United States for the first time.
Truist raised the firm’s price target on BeOne Medicines (ONC) to $448 from $420 and keeps a Buy rating on the shares. The company’s Q3 earnings and the firm’s subsequent…
Citizens raised the firm’s price target on BeOne Medicines (ONC) to $463 from $405 and keeps an Outperform rating on the shares. BeOne raised full-year guidance again on strong performance,…
Barclays analyst Etzer Darout raised the firm’s price target on BeOne Medicines (ONC) to $446 from $415 and keeps an Overweight rating on the shares following the “beat and raise”…
Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key m...
Solid tumor pipeline nears key trials as guidance rises on hematology strength.
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone.
BeOne Medicines AG reported total global revenues of $1.9 billion for the third quarter of 2026, representing an increase of 34% from the prior year. Global sales of BRUKINSA reached $1.4 billion, an ...
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates fr...
BeOne Medicines (ONC) announced that the U.S. Food and Drug Administration has accepted and granted Priority Review to the supplemental New Drug Application for BRUKINSA in combination with rituximab ...
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for BeOne Medicines Ltd. - Sponsored ADR (ONC), delve into some of its key metrics to gain a deeper insight into the company's poten...
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Globa...
BeOne Medicines (ONC) announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology, ESMO, Congre...
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve...
BeOne Medicines (ONC) announced new survival results from the planned second interim analysis and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA ...
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned seco...
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Th...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 577.95M | Analyst x12 | |
| 2027 | 1,029.85M | 78.19% | Analyst x13 |
| 2028 | 1,481.15M | 43.82% | Analyst x8 |
| 2029 | 2,129.57M | 43.78% | Analyst x7 |
| 2030 | 2,772.03M | 30.17% | Analyst x6 |
| 2031 | 3,144.59M | 13.44% | Est @13.4% |
| 2032 | 3,464.39M | 10.17% | Est @10.2% |
| 2033 | 3,737.73M | 7.89% | Est @7.9% |
| 2034 | 3,957.25M | 5.87% | Est @5.9% |
| 2035 | 4,148.11M | 4.82% | Est @4.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | -633.29M | 1.00 | -633.29M |
| 2025A | 941.74M | 1.00 | 941.74M |
| 2026E | 577.95M | 1.08 | Login |
| 2027E | 1.03B | 1.17 | Login |
| 2028E | 1.48B | 1.26 | Login |
| 2029E | 2.13B | 1.36 | Login |
| 2030E | 2.77B | 1.47 | Login |
| 2031E | 3.14B | 1.59 | Login |
| 2032E | 3.46B | 1.71 | Login |
| 2033E | 3.74B | 1.85 | Login |
| 2034E | 3.96B | 2.00 | Login |
| 2035E | 4.15B | 2.16 | Login |
| Terminal | 2.16 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.